Hertz (HTZ) stock skyrockets after the company reported a surprise profit. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts. From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the shares currently trade at 7.75 forward earnings, lower than 15.23 for the industry and the stock’s 5-year mean of 10.54. Higher sales of products like Vyndaqel family, Padcev and Lorbrena are likely to have driven top-line growth.

• Investors may be looking for some reassurance from Pfizer about its growth opportunities in both the short and long term.
• Higher sales of products like Vyndaqel family, Padcev and Lorbrena are likely to have driven top-line growth.
• That being said, if you’re a long-term investor, this can still be a stock worth taking a position in right now, simply because its valuation is so low.
• Meanwhile, a bidding war for Metsera highlights intense competition in the obesity treatment market, with Pfizer’s bid at $8.1 billion falling short of Novo Nordisk’s $10 billion offer.
• In the Specialty Care unit, while sales of Vyndaqel are likely to have remained strong, driven by continued demand growth, sales of Xeljanz and Enbrel are likely to have declined.
• But Pfizer has been trading at a discount for a while, and that hasn’t been enough to get investors on board and believing that it’s a good buy.

Stock , PFE

• Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year.
• While the company has been building out its pipeline and investing in companies to help further its growth, those are steps that will take time.
• Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Dela…

Our experts picked 7 Zacks Rank #1 Strong Buy stocks with the best chance to skyrocket within the next days. Pfizer is one of the largest and most successful drugmakers in oncology. So far this year, Pfizer’s stock has declined 8.4% against an increase of 3.4% for the industry. PFE’s EPS should include a one-time acquired in-process R&D charge related to Pfizer’s recent licensing agreement with Chinese biotech, 3SBio, which closed in July. A Delaware judge said on Wednesday she would reject a request by Pfizer to temporarily block Metsera from terminating its takeover deal with Pfizer, allowing Metsera to proceed instead with a higher $…

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain CMC Markets Review of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025.

It even raised its guidance when it last reported its numbers in August. According to 10 analysts, the average rating for PFE stock is “Hold.” The 12-month stock price target is $27.44, which is an increase of 11.50% from the latest price. Though Pfizer does not expect strong top-line growth over the next three years due to the LOEs, it expects EPS growth.

Pfizer reported another quarter of stagnation, with Q revenue and EPS both declining year-over-year despite beating consensus estimates. To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $85,979 or around 3,488 shares. For a more modest $100 per month or $1,200 per year, you would need $17,206 or around 698 shares. The Zacks Consensus Estimate for sales of the Prevnar family of vaccines is $1.79 billion, while our model estimates Prevnar family vaccine sales to be $1.77 billion. The company is not in a dire situation, which is why I don’t believe it’s a value trap. Investors are discounting it due to market and industry conditions, but if you’re willing to buy and hold and be patient with the stock, I think investing in Pfizer’s stock today can pay off years from now.

Pfizer and Novo Nordisk both raise bids for Metsera

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.

The healthcare bellwether’s performance has been solid, with the company exceeding earnings expectations in each of the trailing four quarters. It delivered a four-quarter earnings surprise of 43.78%, on average. In the last reported quarter, the company delivered an earnings surprise of 34.48%, as seen in the chart below. Pfizer’s Q3 results showed a 5.9% year-over-year decline in sales, totaling $16.65 billion, but the company exceeded EPS estimates by 37%.

Recent News: PFE

ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. That being said, if you’re a long-term investor, this can still be a stock worth taking a position in right now, simply because its valuation is so low. Pfizer hasn’t been trading at its current levels in years, and the business is by no means in bad shape. Its top line grew by 10% last quarter, and its adjusted earnings rose by 30%. Pfizer’s stock has fallen close to 30% in the past five years, but despite its low valuation, investors haven’t been taking the bait. However, the company has been reporting solid results in its recent quarters.

Meanwhile, a bidding war for Metsera highlights intense competition in the obesity treatment market, with Pfizer’s bid at $8.1 billion falling short of Novo Nordisk’s $10 billion offer. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Pfizer records direct sales and alliance revenues from its partner, BioNTech, for the COVID-19 vaccine, Comirnaty.

Metsera said Novo Nordisk’s new bid for the obesity biotech is “superior” to a revised offer from Pfizer, escalating a heated tussle over the startup between the two pharmaceutical giants. A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war for Metsera between Pfizer and Novo Nordisk, but did schedule another hear… Pfizer has removed some conditions in its bid for Metsera as it tries to overcome a rival $10 billion bid by Novo Nordisk for the obesity drug developer, the U.S. drug giant said in a letter to a Dela…

Pfizer Analyst Data

The Zacks Consensus Estimate for sales of Vyndaqel/Vyndamax is $1.63 billion, while our model estimates the same to be $1.64 billion. Among the newer products, sales of the RSV vaccine, Abrysvo, are expected to have been hurt by limited recommendations for RSV vaccinations issued by the US Advisory Committee on Immunization Practices. The Zacks Consensus Estimate for alliance revenues from Eliquis is $1.94 billion, while our model estimate is $1.89 billion. The new offer constitutes a superior company proposal to Pfizer’s bid, Metsera said. Pfizer is preparing to sweeten its offer again for Metsera , the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.6 billion and 66 cents per share, respectively. Estimates for Pfizer’s 2025 earnings have declined from $3.15 to $3.06 per share over the past 30 days. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security.

As of now, Pfizer offers an annual dividend yield of 6.98%, with a quarterly dividend of 43 cents per share ($1.72 a year). However, investors with a long-term horizon should stay invested in this stock due to its cheap valuation, significant upside potential, high dividend yield, and significant growth prospects. Its new drugs and a robust pipeline may help navigate the upcoming LOE period. Last month, Pfizer also signed a drug pricing agreement with the Trump administration. PFE has offered to cut prescription drug prices and boost domestic investments in exchange for a three-year exemption from tariffs on pharmaceutical imports.

Arvinas Inc (ARVN) Q3 2025 Earnings Call Highlights: Clinical Advancements and Strategic …

AstraZeneca (AZN Quick QuoteAZN – Free Report) also signed a similar deal with the Trump administration. For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).

Zacks Research is Reported On:

The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY. In Primary Care, alliance revenues and direct sales from Eliquis are likely to have risen, driven by higher demand trends globally, partially offset by IRA-driven lower pricing and price erosion in some ex-U.S. Sales of the key vaccine Prevnar are likely to have risen, driven by strong uptake of the adult indication.

Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna.

Analysts expect the health care company to report quarterly earnings at 64 cents per share, down from $1.06 per share in the year-ago period. The consensus estimate for Pfizer’s quarterly revenue is $16.52 billion, down from $17.7 billion a year earlier, according to Benzinga Pro. A strong outlook might be what’s necessary to turn things around for the pharma stock.